Македонски Фармацевтски билтен

Macedonian Pharmaceutical Bulletin

волумен **62** (додаток) 2016 / volume **62** (supplement) 2016

Македонско фармацевтско друштво, ул. Маршал Тито 13б/8, Скопје, Македонија
Macedonian Pharmaceutical Association, Marshal Tito 13b/8, Skopje Macedonia

It is our great pleasure to present this Supplement Issue on "*Macedonian Pharmaceutical Bulletin*" to the scientific and professional community. This supplement includes the short communications from the *Sixth Congress of Pharmacy in Macedonia with International participation*, as the largest gathering for the pharmacy profession held in the Republic of Macedonia. The main theme of the Congress was "Modern pharmacist - bridging science with practice".

A broad spectrum of topics within the pharmaceutical sciences and practice carefully selected for this special occasion in order to build up a highly interesting and comprehensive program were covered. The contributions submitted to the Congress included 6 plenary lectures, 84 section lectures, and more that 240 posters. This Congress, followed the excellent international tradition, was attended by close to 1000 domestic and foreign participants. We received 326 short paper submissions from more than 25 countries. These numbers show that our Congress is aiming for the highest scientific standards, and that it can be considered a well-established venue for researchers in the broad fields of Pharmaceutical sciences and practice.

We would like to thank all internationally prominent researchers for their contribution to reinforcing the overall quality of the Congress. They give the state of the art of the recent advances in the field of pharmacy research.

Sincere thanks to the hosts of the Sixth Congress of Pharmacy in Macedonia with International participation, Macedonian Pharmaceutical Association and Faculty of Pharmacy, Ss Cyril and Methodius University in Skopje for their vision and commitments.

We acknowledge the sponsoring companies: the platinium sponsor AD ALKALOID, Skopje, the golden sponsor PLIVA, the silver sponsor EUROFARM and the bronze sponsor SEPTIMA, for the permanent support to our efforts during the organization.

We would also like to thank our members of the Scientific Committee for their volunteer time and dedication to the critical peer review process and in the organization of the program. We also wish to thank all the members of the Organizing Committee, whose work and commitment was invaluable.

On behalf of the Advisory and Scientific Committees, we would like to especially thank the authors, whose work was the essential part of the congress and contributed to a very successful event. Besides the many academic staff and professionals who contributed to the success of the Congress, we are grateful to the students who participated with oral presentations and posters.

The pharmaceutical sciences continue to grow as dynamic scientific interdisciplinary fields. We believe that published short communications will be an excellent source of scientific material in the fast evolving fields in Pharmaceutical sciences and practice.

Chair of the Scientific committee

Prof. Marija Glavas Dodov

Chair of the Organizing committee

Prof. Rumenka Petkovska

Your hosts
Macedonian Pharmaceutical Association
and
Faculty of Pharmacy, Ss Cyril and Methodius University in Skopje

Organizing Committee

Rumenka Petkovska, Ss Cyril and Methodius University, Faculty of Pharmacy / Chair
Zoran Sterjev, Ss Cyril and Methodius University, Faculty of Pharmacy / Co-Chair
Nikola Geskovski, Ss Cyril and Methodius University, Faculty of Pharmacy / Secretary
Jelena Acevska, Ss Cyril and Methodius University, Faculty of Pharmacy
Aleksandra Kapedanovska Nestorovska, Ss Cyril and Methodius University, Faculty of Pharmacy
Arlinda Haxhiu Zaimi, The State University of Tetovo, Faculty of Medical Sciences
Katerina Smilkov, Goce Delcev University, Faculty of Medical Sciences
Gjorge Stojadinovic, Alkaloid AD Skopje

Advisory Board

Svetlana Kulevanova - Macedonia, Suzana Trajkovic Jolevska - Macedonia,
Aleksandar Dimovski - Macedonia, Aneta Dimitrovska - Macedonia, Atila Hinchal –Turkey,
Biljana Bauer - Macedonia, Borut Bozic - Slovenia, Carmen Fernández – Sweden,
Dominik Duchene - France, Jerka Dumic – Croatia, Katerina Goracinova - Macedonia,
Lidija Petrusevska Tozi - Macedonia, Lilian Azzopardi - Malta, Ljubica Suturkova - Macedonia,
Nada Kovacevic - Serbia, Renata Slaveska Raicki – Macedonia, Slobodan Apostolski – Serbia,
Vasia Bankova – Bulgaria, Zoran Kavrakovski - Macedonia

Scientific Committee

Marija Glavas Dodov / Chair
Maja Simonoska Crcarevska / Secretary

Aleksandra Grozdanova - Macedonia
Ana Poceva Panovska - Macedonia
Antonio Makris - Greece
Arijana Meštrović -Croatia
Balázs Hankó - Hungary
César Viseras Iborra - Spain
Dea Baricevik - Slovenia
Dinko Vitezic – Croatia
Dragana Vujanović – Serbia
Ela Hoti - Albania
Emilija Janjevik - Macedonia
Giangiacomo Beretta - Italy
Gjose Stefkov - Macedonia
Jasmina Tonic Ribarska - Macedonia
Jelena Filipovich Grchic - Croatia
Johanes Novak - Austria
Katerina Ancevska Netkovska - Macedonia
Katerina Brezovska - Macedonia
Kristina Mladenovska - Macedonia
Margarida Caramona – Portugal
Marija Hiljadnikova Bajro - Macedonia
Michaele Montagne - USA
Milen I. Georgiev - Bulgaria
Milenko Tanasijevic – USA
Mitko Efremov - Italy
Nasir Behxheti - Macedonia
Nebojsa Menkovic - Serbia
Neda Mimica Dukić - Serbia
Ran Balicer - Israel
Rok Dreu – Slovenia
Rubin Zareski - Macedonia
Rumenka Petkovska - Macedonia
Sasha Baumgartner- Slovenia
Sema Calis – Turkey
Slavica Razic – Serbia
Suela Kellici - Albania
Tatjana Kadifkova Panovska - Macedonia
Vesna Kuntic - Serbia
Vilma Papajani - Albania
Zbigniew Fijałek - Poland
Zoran Sterjev - Macedonia

The present issue *of Macedonian Pharmaceutical Bulletin* is a special issue of the 6th Congress of Pharmacy in Macedonia with international participation.

This issue of *Macedonian Pharmaceutical Bulletin* contains short papers accepted by the scientific committee for the presentation at the Congress.

The authors are fully responsible for the contents of their short papers.

All reviewers that were involved in the short papers revision process are sincerely acknowledged.

Macedonian pharmaceutical bulletin, **62** (suppl) 537 - 538 (2016)
ISSN 1409 - 8695
UDC: 615.849.2.014.2:615.373
Short communication

Development and standardization of Rituximab-conjugates for labeling with Lutetium-177 and Yttrium-90

Emilija Janevik-Ivanovska[1]*, Darinka Gjorgieva Ackova[1], Katarina Smilkov[1], Icko Gjorgoski[2], Trajce Stafilov[3], Petre Makreski [3], Zorica Arsova-Sarafinovska[4], Lajos Baloch[5], Angela Carollo[6], Alberto Signore[7], Adriano Duatti[8]

[1] *Faculty of Medical Sciences, Department of Pharmacy, Goce Delcev University, Krste Misirkov bb, Stip, Republic of Macedonia*
[2] *Faculty of Natural Sciences and Mathematics, Institute of Biology, University "Ss. Cyril and Methodius" , Arhimedova 3, Skopje, Republic of Macedonia*
[3] *Faculty of Natural Sciences and Mathematics, Institute of Chemistry, University "Ss. Cyril and Methodius", Arhimedova 3, Skopje, Republic of Macedonia*
[4] *Institute of Human Health, 50 Divizija 6, Skopje, Republic of Macedonia*
[5] *Department of Nuclear Medicine and Translational Biological Sciences , National Public Health Center, National Research Directorate for Radiobiology and Radiohygiene, Budapest, Hungary*
[6] *European Institute of Oncology, Division of Nuclear Medicine, via Ripamonti, 435, Milano, Italy*
[7] *Nuclear Medicine Unit, Department of Medical-Surgical Sciences and of Translationa Medicine, "Sapienza" University of Rome, Via di Grottarossa 1035, Italy*
[8] *University of Ferrara, Department of Chemical and Pharmaceutical Sciences, Via L. Borsari, 46 Ferrara, Italy*

Introduction

Our work was focused on the investigation for a ready to use prepared freeze dried rituximab immunoconjugates as potential radiopharmaceuticals for labeling with Lu-177 and Y-90 in order to increase the stability and higher efficiency and lower toxicity. We tested three bifunctional chelating agents (BFCA's), *p*-SCN-Bn-DOTA, *p*-SCN-Bn-DTPA and 1B4M-DTPA conjugated to the same antibody using previously established protocol for conjugation (Gjorgieva Ackova, 2014, 2015; Smilkov, 2014).

The main goal was to investigate chemical characterization of the immunoconjugates, labeled with "cold" non-radioactive isotopes of Lutetium and Yttrium in the same conditions as with radioactive Lutetium 177 and to show the chemical behavior and toxicological properties.

Material and method

The conjugation of antibody with three different bifunctional cleating agents was performed using using previously established protocol for conjugation. The concentrations were adjusted to 1 mg/mL and the solutions were then lyophilized.

The purified immunoconjugates were formulated in absence of any cryoprotectant at the concentration of 10 mg/mL, and subsequently lyophilized according to selected protocols.

The process of freeze drying was completed using Labconco Free Zone Stoppering Tray Dryer, (USA), using protocol described by Park in 2013, modified to our experience.

Concentration of the antibody/immunoconjugate was determinate before and after freeze drying and reconstitution using UV spectrophotometer (Jenway UV/VIS spectrophotometer 6715), and semi-micro UV polypropylene tubes with 0.1M PBS pH=8.0, at 280 nm in triplicate.

After freeze drying both characterization of the conjugates and determination of the average number of BFCA attached to each antibody molecule is performed by MALDI-TOF mass spectrometry and integrity of the antibody was evaluated using SDS-PAGE electrophoresis, on 12% bis-tris acrylamide gel.

The spectroscopic characterization of all three freeze dried immunoconjugates, in terms of monitoring the secondary protein structure (and its preservation), was achieved

* emilija.janevik@ugd.edu.mk

by FT-IR and Raman spectroscopy.

The freeze dying immunoconjugates after reconstitution were labeling with Lu-177 (555 MBq/mg in 0,5 M NH_4OAc) and radiochemical purity was determined by instant thin-layer chromatography on silica plates with a mobile phase of ammonium acetate : methanol (1 : 1) using Cyclone Plus Phosphore Imager (Perkin Elmer).

The obtained radioimmunoconjugates were characterized by SE-HPLC, using a Zorbax Bio Series GF-250 column and the elution process was monitored on UV detector at 280 nm and radiodetector (Wojdowska, 2014).

Toxicological studies were performed in Wistar rats after injection of rituximab labeled with cold Lutetium and Yttrium. Biodistribution studies were performed in 5-6 week old nude mice grafted with Raji cells ($2x10^6$ cells in 0.5 mL medium solution) after injection of radioactive Lu-177-Rituximab.

Results and discussion

The 3 day protocol of freeze drying without the presence of mannitol, showed the greatest similarity in the elution profiles of the immunoconjugate prior lyophilization (Gholipour, 2014).

After freeze drying, the pellets obtained corresponded to the composition and the time until complete reconstitution after addition of saline showed no significant difference in the time of complete dissolution of the lyophilisates, i.e. all tested samples were completely reconstituted in 2 min.

The average number of BFCA attached to each antibody molecule performed by MALDI-TOF mass spectrometry shows presence of two main peaks corresponding to MW of 146491 Da (unconjugated antibody) and 149873 Da (conjugated antibody) which corresponds to an average of 6.1 groups of *p*-SCN-Bn-DOTA (M = 551.61 g·mol-1), two peaks also, corresponding to MW of 146477 Da (unconjugated antibody) and 151246 Da (conjugated antibody) corresponds to an average of 8.8 groups of *p*-SCN-Bn-DTPA (M = 540.54 g·mol-1) attached to a molecule of rituximab and two peaks corresponding to MW of 146848 Da (unconjugated antibody) and 151506 Da (conjugated antibody) corresponding to average of 8.3 groups 1B4M-DTPA (M = 555.58 g·mol-1) attached to a molecule of rituximab.

All immunoconjugates (both before and after lyophilization) were separated in two distinct Mw species which migrated in two bands (upper at ~50 kDa and lower at ~25 kDa) confirming the migration behavior typical for IgG antibodies which are composed of twoidentical subunits each composed by two polypeptide chains: two heavy and two light chains, linked via 4 disulfide bonds. The obtained fragments correspond to molecular masses of rituximab heavy and light chain given at the literature (Bil, 2007;)

In the experimental IR (in the region 2000-500 cm^{-1}) and Raman spectra (2000–400 cm^{-1} region) we observed retaining of native structure of the antibody and no obvious aggregation.

The radiochemical purity and determination of radioimmunoconjugates by SE-HPLC, obtained after radiolabeling the with Lu-177 was higher than 5%. These conjugates were stable for 48h in 0.9% NaCl, however, progressive aggregation was observed.

Animal studies showed no toxicity and SPECT images in mice showed good localization of the tumor, as confirmed by ex-vivo organ counting.

Conclusion

After evaluation of all the obtained results obtained we can conclude:

- Three immunoconjugates were synthesized, using *p*-SCN-Bn-DOTA, *p*-SCN-Bn-DTPA and 1B4M-DTPA using the a selected ratio, 1:20
- Protocol for lyophilization was established, yielding lyophilisates with favorable physicochemical properties.
- The non-radioactive labeling with Y and Lu showed preserved secondary structure in all three types of immunoconjugate, confirming their stability in conditions of freeze-drying and labeling
- During labeling with Lu-177 all three types of radioimmunoconjugates showed high radiochemical purity, over 95%, which was confirmed both in ITLC and SE-HPLC.

The selection of the most appropriate immunoconjugate kit suitable for labeling with Lu-177 or with Y-90 can be made after stability study of the formulation and completition of cell culture studies.

References

Bil, J., Winiarska, M., 2007. Molecular mechanisms of the therapeutic activity of Rituximab. The monoclonal antibody against CD20 antigen. Adv. Cell Biol. 34(2), 335-359.

Gholipour, N., Jalilian, A.R., Khalaj, A., Johari-Daha, F., Yavari, K., Sabzevari, O., Khanchi, A.R., Akhlaghi, M., 2014. Preparation and radiolabeling of a lyophilized (kit) formulation of DOTA-rituximab with 90Y and 111In for domestic radioimmunotherapy and radioscintigraphy of Non-Hodgkin's Lymphoma. DARU J. Pharm. Sci. 22(58), 1-10.

Gjorgieva Ackova, D., Smilkov, K., Janevik-Ivanovska, E., 2014. Formulation and Characterization of "Ready to Use" 1B4M-DTPA-rituximab for Lu-177 Labeling. World J. Med. Sci. 11(4), 535-540.

Gjorgieva Ackova, D., Smilkov, K., Janevik-Ivanovska, E., Stafilov, T., Arsova-Sarafinovska, Z., Makreski, P. 2015. Evaluation of Non-radioactive Lutetium- and Yttrium-labeled Immunoconjugates of Rituximab – A Vibrational Spectroscopy Study. Maced. J. Chem. Chem. Eng. 34, 351–362.

Smilkov, K., Gjorgieva Ackova D., Gjorgovski, I., Janevik-Ivanovska, E., 2014. Rituximab-immunoconjugate kit-formulations for NHL radioimmunotherapy. Physioacta 8(2), 113-120.

Wojdowska, W., Karczmarczyk, U., Maurin, M., Sawicka, A., Laszuk, E., Garnuszek, P., Mikolajczak, R., 2014. In virto and in vivo investigations of 177Lu and 90Y labeled DOTA(SCN)-Rituximab radioimmunoconjugates. Q. J. Nucl. Med. Mol. Imaging 58, 45.

CONTENTS

Opening lecture

Closing lecture

Plenary lectures

Pharmacoeconomy / Social pharmacy / Drug information

Pharmaceutical analysis / Quality assurance / Regulatory affairs

Clinical biochemistry / Toxicology / Food and nutrition

Pharmaceutical technology and biotechnology/ Cosmetology / Biopharmacy

Medicinal and aromatic plants

Clinical pharmacy / Pharmaceutical chemistry / Biomolecular sciences

Continual professional development

Student session